Literature DB >> 21791624

Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats.

Kuan-Hsing Chen1, Mei-Ling Cheng, Yu-Hong Jing, Daniel Tsun-Yee Chiu, Ming-Shi Shiao, Jan-Kan Chen.   

Abstract

Diabetes mellitus (DM) is characterized by dysregulated energy metabolism. Resveratrol (RSV) has been shown to ameliorate hyperglycemia and hyperlipidemia in diabetic animals. However, its overall in vivo effects on energy metabolism and the underlying mechanism require further investigation. In the present study, electrospray ionization-tandem mass spectrometry was employed to characterize the urine and plasma metabolomes of control, streptozotocin-induced DM and RSV-treated DM rats. Using principal component analysis (PCA) and heat map analysis, we discovered significant differences among control and experimental groups. RSV treatment significantly reduced the metabolic abnormalities in DM rats. Compared with the age-matched control rats, the level of carnitine was lower, and the levels of acetylcarnitine and butyrylcarnitine were higher in the urine and plasma of DM rats. RSV treatment ameliorated the deranged carnitine metabolism in DM rats. In addition, RSV treatment attenuated the diabetic ketoacidosis and muscle protein degradation, as evidenced from the attenuation of elevated urinary methyl-histidine and plasma branched-chain amino acids levels in DM rats. The beneficial effects of RSV in DM rats were correlated with activation of hepatic AMP-activated protein kinase and SIRT1 expression, increase of hepatic and muscular mitochondrial biogenesis and inhibition of muscle NF-κB activities. We concluded that RSV possesses multiple beneficial metabolic effects in insulin-deficient DM rats, particularly in improving energy metabolism and reducing protein wasting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21791624     DOI: 10.1152/ajpendo.00048.2011

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  23 in total

1.  Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism.

Authors:  Nima Alamdari; Zaira Aversa; Estibaliz Castillero; Aniket Gurav; Victoria Petkova; Steven Tizio; Per-Olof Hasselgren
Journal:  Biochem Biophys Res Commun       Date:  2011-12-07       Impact factor: 3.575

2.  Development, brain plasticity and reward: early high-fat diet exposure confers vulnerability to obesity-view from the chair.

Authors:  C-D Walker
Journal:  Int J Obes Suppl       Date:  2012-12-11

3.  Sirtuin biology and relevance to diabetes treatment.

Authors:  X Charlie Dong
Journal:  Diabetes Manag (Lond)       Date:  2012-05

4.  Activation of AMPK in Human Placental Explants Impairs Mitochondrial Function and Cellular Metabolism.

Authors:  Daphne Landau; Maricela Haghiac; Judi Minium; Yelenna Skomorovska-Prokvolit; Virtu Calabuig-Navarro; Perrie O'Tierney-Ginn
Journal:  Reprod Sci       Date:  2018-05-22       Impact factor: 3.060

Review 5.  Novel treatment strategies for chronic kidney disease: insights from the animal kingdom.

Authors:  Peter Stenvinkel; Johanna Painer; Makoto Kuro-O; Miguel Lanaspa; Walter Arnold; Thomas Ruf; Paul G Shiels; Richard J Johnson
Journal:  Nat Rev Nephrol       Date:  2018-01-15       Impact factor: 28.314

6.  Nicotinuric acid: a potential marker of metabolic syndrome through a metabolomics-based approach.

Authors:  Chun-Feng Huang; Mei-Ling Cheng; Chun-Ming Fan; Chuang-Ye Hong; Ming-Shi Shiao
Journal:  Diabetes Care       Date:  2012-12-28       Impact factor: 19.112

7.  The Tellurium compound, AS101, increases SIRT1 level and activity and prevents type 2 diabetes.

Authors:  Meital Halperin-Sheinfeld; Asaf Gertler; Eitan Okun; Benjamin Sredni; Haim Y Cohen
Journal:  Aging (Albany NY)       Date:  2012-06       Impact factor: 5.682

8.  Serum glycine is associated with regional body fat and insulin resistance in functionally-limited older adults.

Authors:  Michael S Lustgarten; Lori Lyn Price; Edward M Phillips; Roger A Fielding
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 9.  Resveratrol: why is it a promising therapy for chronic kidney disease patients?

Authors:  Juliana F Saldanha; Viviane de O Leal; Peter Stenvinkel; José Carlos Carraro-Eduardo; Denise Mafra
Journal:  Oxid Med Cell Longev       Date:  2013-12-29       Impact factor: 6.543

Review 10.  Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans.

Authors:  J Gambini; M Inglés; G Olaso; R Lopez-Grueso; V Bonet-Costa; L Gimeno-Mallench; C Mas-Bargues; K M Abdelaziz; M C Gomez-Cabrera; J Vina; C Borras
Journal:  Oxid Med Cell Longev       Date:  2015-06-28       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.